MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells

[1] Siegel R(2013)Cancer statistics, 2013 CA Cancer J Clin 63 11-30

[2] Naishadham D(2011)Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARgamma independent manner PLoS One 6 938-948

[3] Jemal A(2012)Ovarian cancer risk factors by histologic subtypes in the NIH-AARP diet and health study Int J Cancer 131 111951-151

[4] Al-Alem L(2020)Potential cytotoxic and anti-metastatic effects of berberine on gynaecological cancers with drug-associated resistance Eur J Med Chem 187 119-437

[5] Yang HP(2015)microRNA and ovarian cancer Adv Exp Med Biol 889 427-281

[6] Mortazavi H(2017)Epidemiology and treatment patterns of epithelial ovarian cancer Expert Rev Anticancer Ther 17 626-725

[7] Langhe R(2016)Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments Ecancermedicalscience 10 275-147

[8] Jessmon P(2009)Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer Gynecol Oncol 112 719-2065

[9] Lokadasan R(2011)Rethinking ovarian cancer: recommendations for improving outcomes Nat Rev Cancer 11 139-501

[10] Muggia F(2005)Role of chemotherapy in the management of epithelial ovarian cancer Expert Rev Anticancer Ther 5 2057-50

[1] Siegel R(2013)Cancer statistics, 2013 CA Cancer J Clin 63 11-30

[2] Naishadham D(2011)Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARgamma independent manner PLoS One 6 938-948

[3] Jemal A(2012)Ovarian cancer risk factors by histologic subtypes in the NIH-AARP diet and health study Int J Cancer 131 111951-151

[4] Al-Alem L(2020)Potential cytotoxic and anti-metastatic effects of berberine on gynaecological cancers with drug-associated resistance Eur J Med Chem 187 119-437

[5] Yang HP(2015)microRNA and ovarian cancer Adv Exp Med Biol 889 427-281

[6] Mortazavi H(2017)Epidemiology and treatment patterns of epithelial ovarian cancer Expert Rev Anticancer Ther 17 626-725

[7] Langhe R(2016)Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments Ecancermedicalscience 10 275-147

[8] Jessmon P(2009)Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer Gynecol Oncol 112 719-2065

[9] Lokadasan R(2011)Rethinking ovarian cancer: recommendations for improving outcomes Nat Rev Cancer 11 139-501

[10] Muggia F(2005)Role of chemotherapy in the management of epithelial ovarian cancer Expert Rev Anticancer Ther 5 2057-50